Molecular diagnostic stratification of AML - integrating molecular biomarkers into clinical diagnostics in AML
Online conference registration is due to close shortly. If online registration has closed and you would like to attend the AML workshop, please contact email@example.com to book a place.
The aim of this workshop is to highlight advances in defining pre treatment genomic variation with prognostic relevance in AML together with patient specific, post treatment indicators of response to induction therapy to greater refine risk adapted management of AML.
AML is genetically a highly heterogenous disease. Defining individual genetic markers or networks of markers with prognostic significance and their respective relationship to pre treatment clinical characteristics presents a major challenge to diagnostic laboratories offering a haemato oncology service. In addition the potential to integrate panels of pre treatment parameters with post treatment assessment of minimal residual disease levels to improve risk stratification will be considered.
Tuesday May 1st 2012, 13.45-16.30hrs
Rate for attendance at AML workshop only: £50
- Chair: Dr Manoj Raghavan
- 13:45 Professor Charlie Craddock, Birmingham - Welcome.
- 14:00 Dr Vera Grossman, Munich - Novel molecular insights into AML using amplicon deep-sequencing.
- 14:30 Professor David Grimwade, London - Molecular markers for MRD in AML.
- 15:00 Dr Lars Bullinger, Ulm - "Omic" profiling in AML - epigenomics opens new avenues.
- 15:30 Dr Peter Campbell, Cambridge - Genomic architecture of MDS/AML.
- 16:00 Dr Jude Fitzgibbon, London - The Genetics of Familial AML.